5:27 PM
Oct 02, 2012
 |  BC Extra  |  Top Story

ArQule slides on trial discontinuation

ArQule Inc. (NASDAQ:ARQL) fell $2.81 (56%) to $2.18 on Tuesday after it and Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) discontinued the Phase III MARQUEE trial in non-small cell lung cancer after an interim analysis showed tivantinib plus Tarceva erlotinib would miss the primary endpoint of overall survival (OS) vs. Tarceva alone. The partners said that...

Read the full 269 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >